- Home
- GRF vs ANEB Comparison
GRF vs ANEB Comparison
Compare GRF & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | ANEB |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 46.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRF | ANEB |
|---|---|---|
| Price | $10.97 | $1.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0K | ★ 149.4K |
| Earning Date | 01-01-0001 | 02-13-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.93 | $0.90 |
| 52 Week High | $10.19 | $3.42 |
Technical Indicators
Market Signals| Indicator | GRF | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 27.44 |
| Support Level | $10.36 | $1.01 |
| Resistance Level | $11.05 | $1.12 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 49.75 | 36.41 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.